

SUPPLEMENTARY MATERIALS

The Impact of Migraine on the Whole Life Course of Patients: Results from the OVERCOME (Japan) 2nd Study

Authors: Daisuke Danno, MD, PhD¹; Shiho Suzuki, MD, PhD²; Tsubasa Takizawa, MD, PhD³; Ryotaro Ishii, MD, PhD⁴; Masayuki Hamakawa, PhD⁵; Yoshinori Tanizawa, PhD⁶; Satoshi Osaga, PhD⁶; Mika Komori, MD, PhD⁶

¹Tominaga Hospital, Osaka, Japan; ²Dokkyo Medical University, Mibu, Japan;

³Keio University School of Medicine, Tokyo, Japan; ⁴Kyoto Prefectural University of Medicine, Kyoto, Japan; ⁵Social Survey Research Information Co., Ltd, Tokyo,

Japan; ⁶Eli Lilly Japan, Kobe, Japan

Corresponding author:

Yoshinori Tanizawa,

Japan Value Evidence and Outcomes,

Eli Lilly Japan K.K.

5-1-28 Isogami-dori, Chuo-ku,

Kobe 651-0086,

Japan.

E-mail: tanizawa_yoshinori@lilly.com

Phone: +81 (78) 2429624

Table S1: Patient-reported outcomes

PRO	Evaluation	Scoring	Grading
MIDAS	Quantifies headache-related disability over a 3-month period. It measures the number of days missed or with reduced productivity at work, home, or social events.	The total score is a summation of five items (scored 0–90); higher values indicate greater disability.	Grade I (0–5) – little or no disability, Grade II (6–10) – mild disability, Grade III (11–20) – moderate disability, and Grade IV (21+) – severe disability.
MIDAS additional question on pain severity	Patients self-report average headache pain severity on an 11-point numerical rating scale.	0 (no pain at all) to 10 (pain as bad as it could be).	-
HIT-6	A 6-item scale that measures the impact of headaches on activities in work, school, home, and society.	Scored 36–78; higher scores indicate greater interference in daily life.	Little-to-no impact (36–49), Moderate impact (50–55), Substantial impact (56–59), and Severe impact (60–78).
MIBS-4	A 4-item instrument that measures headache-related burden in the time between attacks. The items address disruption at work and school, diminished family and social life, difficulty planning, and emotional difficulty.	The total score range is 0–12.	Level of interictal burden is categorized as None (0), Mild (1–2), Moderate (3–4), and Severe (5+).
WPAI	A 6-item instrument that measures the impact on work productivity and regular activities attributable to migraine. Four domains - absenteeism, presenteeism, work productivity loss (only for employed respondents), and activity impairment.	Scores are calculated as impairment percentages; higher numbers indicate greater impairment and less productivity.	-
IMPAC	A 12-item instrument that measures the impact of migraine on the family, i.e., activity, partner, and child interaction.	Calculated as the difference in score compared to the mean score.	Grade I (none/mild), Grade II (moderate), Grade III (severe), and Grade IV (very severe).

Abbreviations: HIT-6 – Headache Impact Test-6, IMPAC – Impact of Migraine on Partners and Adolescent Children Scale, MIBS – Migraine Interictal Burden Scale-4, MIDAS – Migraine Disability Assessment Scale, PRO – Patient-Reported Outcome, WPAI – Work Productivity and Activity Impairment Questionnaire

Figure S1: Medical management history of the 0–3 MHD migraine subgroup

Each panel describes the activity in the respondents' journey, the proportion of respondents initiating that activity among the 14,734 respondents with 0–3 MHD, and the mean age. The orange bars indicate the proportion of respondents at each disability level and the blue bars indicate the proportion of respondents with the corresponding headache frequency. ^a Includes prescriptions except triptans and lasmiditan. **Abbreviations:** MHD – Monthly Headache Days, OTC – Over-the-counter.






Figure S2: Medical management history of the 4–7 MHD migraine subgroup

Each panel describes the activity in the respondents' journey, the proportion of respondents initiating that activity among the 2545 respondents with 4–7 MHD, and the mean age. The orange bars indicate the proportion of respondents at each disability level and the blue bars indicate the proportion of respondents with the corresponding headache frequency. ^a Includes prescriptions except triptans and lasmiditan. **Abbreviations:** MHD – Monthly Headache Days, OTC – Over-the-counter.


Headache onset (100%) – 17.4y



1st doctor visit (65.6%) – 26.8y



Migraine diagnosis (49.3%) – 27.7y




Level of disability	Description
I	I work or function normally
II	Working ability or activity impaired to some degree
III	Working ability or activity severely impaired, but no need to lie down and rest
IV	Need to lie down and rest


Headache frequency	Description
I	Several times a year
II	About once a month
III	2–3 times a month
IV	1 time per week
V	2–3 times a week
VI	Almost every day

Patient Journey Over Time


Start OTC (89.9%) – 19.0y



1st acute care prescription^a (58.7%) – 26.8y



1st oral preventive drug (30.4%) – 28.5y



1st triptan prescription (16.8%) – 31.4y






Figure S3: Medical management history of the 8–14 MHD migraine subgroup

Each panel describes the activity in the respondents' journey, the proportion of respondents initiating that activity among the 1316 respondents with 8–14 MHD, and the mean age. The orange bars indicate the proportion of respondents at each disability level and the blue bars indicate the proportion of respondents with the corresponding headache frequency. ^a Includes prescriptions except triptans and lasmiditan. **Abbreviations:** MHD – Monthly Headache Days, OTC – Over-the-counter


Headache onset (100%) – 17.4y



1st doctor visit (69.0%) – 26.6y




Migraine diagnosis (54.3%) – 27.9y




Level of disability	Description
I	I work or function normally
II	Working ability or activity impaired to some degree
III	Working ability or activity severely impaired, but no need to lie down and rest
IV	Need to lie down and rest
Headache frequency	Description
I	Several times a year
II	About once a month
III	2~3 times a month
IV	1 time per week
V	2~3 times a week
VI	Almost every day

Patient Journey Over Time


Start OTC (88.8%) – 19.0y



1st acute care prescription^a (62.6%) – 27.1y



1st oral preventive drug (32.3%) – 29.5y



1st triptan prescription (18.9%) – 30.8y






Figure S4: Medical management history of the ≥15 MHD migraine subgroup

Each panel describes the activity in the respondents' journey, the proportion of respondents initiating that activity among the 995 respondents with ≥15 MHD, and the mean age. The orange bars indicate the proportion of respondents at each disability level and the blue bars indicate the proportion of respondents with the corresponding headache frequency. ^a Includes prescriptions except triptans and lasmiditan. **Abbreviations:** MHD – Monthly Headache Days, OTC – Over-the-counter.


Headache onset (100%) – 17.5y



1st doctor visit (72.0%) – 25.5y




Migraine diagnosis (53.8%) – 26.8y




Level of disability	Description
I	I work or function normally
II	Working ability or activity impaired to some degree
III	Working ability or activity severely impaired, but no need to lie down and rest
IV	Need to lie down and rest
Headache frequency	Description
I	Several times a year
II	About once a month
III	2~3 times a month
IV	1 time per week
V	2~3 times a week
VI	Almost every day

Patient Journey Over Time


Start OTC (83.7%) – 18.9y



1st acute care prescription^a (65.3%) – 28.0y



1st oral preventive drug (35.6%) – 28.8y



1st triptan prescription (18.7%) – 29.2y

